Vascular Biogenics (NASDAQ: VBLT) and MEI Pharma (NASDAQ:MEIP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitabiliy.

Valuation & Earnings

This table compares Vascular Biogenics and MEI Pharma’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Vascular Biogenics N/A N/A -$16.52 million ($0.63) -6.58
MEI Pharma $22.80 million 4.27 $1.06 million $0.01 265.27

MEI Pharma has higher revenue and earnings than Vascular Biogenics. Vascular Biogenics is trading at a lower price-to-earnings ratio than MEI Pharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vascular Biogenics and MEI Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Vascular Biogenics N/A -36.93% -33.59%
MEI Pharma N/A 2.57% 2.20%

Analyst Recommendations

This is a breakdown of current recommendations for Vascular Biogenics and MEI Pharma, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vascular Biogenics 0 0 4 0 3.00
MEI Pharma 0 0 2 0 3.00

Vascular Biogenics presently has a consensus price target of $14.75, suggesting a potential upside of 255.72%. MEI Pharma has a consensus price target of $6.75, suggesting a potential upside of 154.72%. Given Vascular Biogenics’ higher probable upside, analysts plainly believe Vascular Biogenics is more favorable than MEI Pharma.

Volatility and Risk

Vascular Biogenics has a beta of -3.11, indicating that its stock price is 411% less volatile than the S&P 500. Comparatively, MEI Pharma has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500.

Institutional & Insider Ownership

14.0% of Vascular Biogenics shares are held by institutional investors. Comparatively, 17.5% of MEI Pharma shares are held by institutional investors. 4.6% of MEI Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

MEI Pharma beats Vascular Biogenics on 8 of the 10 factors compared between the two stocks.

Vascular Biogenics Company Profile

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. Its lead product candidate, VB-111(ofranergene obadenovec), is a gene-based biologic that it is developing for solid tumor indications, with a program for recurrent glioblastoma (rGBM), a form of brain cancer. It also is engaged in conducting a program focusing anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules it developed that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. The lead product candidate from this program, VB-201, is a Phase II-ready molecule.

MEI Pharma Company Profile

MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company’s portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. PWT143 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.

Receive News & Stock Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related stocks with our FREE daily email newsletter.